Patients with prostate cancer progression after hormone therapy or exhibiting hormone resistance or those having prostate cancer with high TMB or HRD/DRD, or MSI-H or accompanied with CDK12 changes or AR-V7+ characteristics can receive ICI combination therapies (ORR, 10–40%; mOS, 8.2–19 months) [202]. Here, CDK12 is linked to prostate carcinoma.